🟠 Moderate Evidence
Marketing claims that chelated magnesium supplements are “four times more bioavailable” than cheaper oxide forms lack support in rigorous human trials. The most-cited head-to-head study—a double-blind, randomized crossover trial published in the Journal of Parenteral and Enteral Nutrition (1994)—found absorption rates of 23.5% for magnesium chelate versus 22.8% for oxide, a statistically insignificant difference of 0.7 percentage points in the full patient cohort.
Key takeaways
- A landmark bioavailability trial found chelated and oxide magnesium were essentially equivalent (23.5% vs 22.8% absorption)
- The “4× more bioavailable” claim originates from a post-hoc subgroup of only four patients, not the full trial population
- Marketing materials have omitted subgroup context and combined study findings to create unsupported superiority claims
Study at a Glance
| Source | Journal of Parenteral and Enteral Nutrition |
| Study type | Double-blind, randomized crossover trial |
| Sample size | N = 12 patients |
| Population | Patients with ileal resections |
| Country | United States |
Magnesium Absorption: What the Data Actually Show
Percentage absorption by form, measured by stable isotope tracing (Schuette et al., 1994)
Source: Schuette et al., Journal of Parenteral and Enteral Nutrition, 1994 | Georgian Medical Journal News
The Trial That Launched a Marketing Story
In 1994, researchers led by Schuette, Lashner, and Janghorbani published a carefully designed trial comparing magnesium chelate (diglycinate) against magnesium oxide in 12 patients with ileal resections—a population with impaired intestinal absorption. Using stable isotope tracing, the most rigorous method available for measuring magnesium absorption, they administered 100 mg doses of labeled magnesium in each form and measured fractional absorption.
The results were clear: absorption of chelate was 23.5%, and absorption of oxide was 22.8%. According to the published data, this 0.7 percentage point difference was not statistically significant. In the full trial cohort, the two forms were functionally equivalent.
How a Subgroup Finding Became Industry Canon
The “chelate is superior” narrative, however, did not rest on the full-cohort finding. Instead, supplement manufacturers extracted data from a post-hoc subgroup analysis of the four most absorption-impaired patients in the trial. In this small group, chelate showed 23.5% absorption while oxide showed only 11.8%—a meaningful difference that contradicted the full-cohort result.
This subgroup finding was then mathematically recombined with separate data: Firoz and Graber’s 2001 measurement of magnesium oxide absorption in healthy volunteers, which yielded a 4% figure. By dividing the subgroup chelate absorption (23.5%) by the oxide estimate from healthy people (4%)—not by the oxide absorption in the same trial (22.8%)—marketers arrived at the widely cited “chelate is 5.9 times more bioavailable” or rounded to “4 times more bioavailable” claim now ubiquitous on retail shelves, according to analysis of marketing materials cited in the source report.
In the full patient cohort of the landmark bioavailability trial, chelated magnesium and magnesium oxide showed absorption rates of 23.5% and 22.8%, respectively—a non-significant difference of 0.7 percentage points.
— Schuette et al., Journal of Parenteral and Enteral Nutrition (1994)
What This Means for Supplement Consumers
The marketing separation of subgroup findings from their population context represents a systematic misrepresentation of evidence. The trial was designed to answer whether chelate is superior in absorption. The full-cohort answer was no. The subgroup finding, while worth noting in discussions of impaired absorption, cannot ethically be extracted, recontextualized, and multiplied against unrelated data to support a blanket superiority claim.
What this means
Frequently asked questions
Does chelated magnesium absorb better than oxide?
In the most-cited head-to-head trial using stable isotope tracing, the gold-standard absorption measurement, chelated and oxide magnesium showed nearly identical absorption rates (23.5% vs 22.8%) in the full patient cohort. The difference was not statistically significant. The “four times better” claim comes from a post-hoc subgroup of four patients, not the full trial population.
Why is chelated magnesium so much more expensive?
Chelated magnesium is more expensive to manufacture because magnesium is bound to amino acids (like glycine), requiring additional processing. The price premium is justified by manufacturing cost, not by superior absorption or efficacy in most populations, according to the bioavailability evidence reviewed above.
Are there cases where chelated magnesium is actually better?
In the Schuette trial, the small subgroup with the most severe absorption impairment (ileal resection patients) showed better absorption with chelate. However, this finding cannot be generalized to healthy people or those with mild digestive issues, and the full-cohort result was not statistically different between forms. Consult a healthcare provider about individual needs.
As the supplement industry continues to market magnesium products to health-conscious consumers, the gap between marketing claims and rigorous evidence deserves scrutiny. The next time you see a supplement label claiming superior bioavailability, ask whether that claim rests on full-trial data or on a recontextualized subgroup finding. For the magnesium category, the answer is clear: the evidence does not support the premium price.
Source: Schuette et al., Journal of Parenteral and Enteral Nutrition, 1994; Marketing analysis from source report
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
